🤑 It doesn’t get more affordable. Grab this 60% OFF Black Friday offer before it disappears…CLAIM SALE

$1.8M Bet On This Health Care Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

Published 14/06/2024, 12:15
© Reuters.  $1.8M Bet On This Health Care Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
ACRS
-
ZOM
-

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

The Dow Jones index closed lower by around 0.2% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

Aclaris Therapeutics

  • The Trade: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) 10% owner Braden Michael Leonard bought a total of 1,611,200 shares at an average price of $1.11. To acquire these shares, it cost around $1.78 million.
  • What's Happening: On May 7, Aclaris Therapeutics posted upbeat quarterly results.
  • What Aclaris Therapeutics Does: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States.
Zomedica
  • The Trade: Zomedica Corp. (NYSE:ZOM) Vice President of Sales Russell Kevin Klass acquired a total of 299,993 shares at an average price of $0.16. To acquire these shares, it cost around $46,529.
  • What's Happening: On May 15, Zomedica announced the launch of Over-the-Air software and firmware update capability for its TRUFORMA point-of-care diagnostic platform.
  • What Zomedica Does: Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians.
Perspective Therapeutics
  • The Trade: Perspective Therapeutics, Inc. (NASDAQ:CATX) CEO Johan M. Spoor acquired a total of 100,000 at an average price of $1.17. The insider spent around $117,430 to buy those shares.
  • What's Happening: On June 11, Perspective Therapeutics announced a 1-for-10 reverse stock split.
  • What Perspective Therapeutics Does: Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body.
Now Read This: Top 3 Tech Stocks That May Fall Off A Cliff This Month

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.